<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sugammadex: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sugammadex: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sugammadex: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="105866" href="/d/html/105866.html" rel="external">see "Sugammadex: Drug information"</a> and <a class="drug drug_patient" data-topicid="106055" href="/d/html/106055.html" rel="external">see "Sugammadex: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F46127879"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bridion</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871639"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Bridion</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F46129143"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote</span>;</li>
<li>
<span class="list-set-name">Selective Relaxant Binding Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F46146793"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b714b2fb-6174-471e-b3c3-30fc89286aca">Routine reversal of rocuronium-induced moderate blockade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Routine reversal of rocuronium-induced moderate blockade:</b> Limited data available: Infants and Children &lt;2 years: IV bolus: 2 mg/kg or 4 mg/kg as a single dose given over 10 seconds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31406051','lexi-content-ref-19194156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31406051','lexi-content-ref-19194156'])">Ref</a></span>). Dosing based on a multicenter, randomized, parallel-group, dose-finding study in surgical patients (n=91 [63 pediatric patients]; age range: 28 days to 17 years) and a dose-response study in pediatric surgical patients (n=75; age range: 2 to 23 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31406051','lexi-content-ref-19194156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31406051','lexi-content-ref-19194156'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d2a29495-25fe-4fab-9062-967390a2cf0a">Routine reversal of rocuronium- or vecuronium-induced blockade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Routine reversal of rocuronium- or vecuronium-induced blockade: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosing based on actual body weight. Doses and timing of administration based on monitoring for twitch responses and the extent of spontaneous recovery that has occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Deep level of neuromuscular block (ie, spontaneous recovery of twitch response of 1 to 2 post-tetanic counts and zero twitch response following train-of-four [TOF] stimulation):</i> IV bolus: 4 mg/kg as a single dose given over 10 seconds.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Moderate level of neuromuscular block (ie, after appearance of the second twitch following TOF stimulation):</i> IV bolus: 2 mg/kg as a single dose given over 10 seconds.</p>
<p style="text-indent:-2em;margin-left:4em;">Readministration of rocuronium or vecuronium: Following sugammadex use for routine reversal, waiting times for readministration of rocuronium or vecuronium vary greatly (5 minutes to 24 hours) depending on agent, dose, and renal function (consult product labeling); if immediate neuromuscular blockade is needed, a nonsteroidal neuromuscular-blocking agent (eg, cisatracurium, atracurium) may be required.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51220183"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 80 mL/minute/1.73 m<sup>2</sup>: There are no pediatric-specific recommendations in manufacturer's labeling; based on experience in adult patients, no dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Dialysis: Use is not recommended.</p></div>
<div class="block dohp drugH1Div" id="F51220184"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution, particularly if accompanied by coagulopathy or severe edema.</p></div>
<div class="block doa drugH1Div" id="F46021169"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="105866" href="/d/html/105866.html" rel="external">see "Sugammadex: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing based on actual body weight. Doses and timing of administration based on monitoring for twitch responses and the extent of spontaneous recovery that has occurred.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d2a29495-25fe-4fab-9062-967390a2cf0a">Routine reversal of rocuronium- or vecuronium-induced blockade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Routine reversal of rocuronium- or vecuronium-induced blockade:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Deep block (at least 1 to 2 post-tetanic counts and prior to the second twitch following train-of-four [TOF] stimulation): 4 mg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22698066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22698066'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate block (after appearance of the second twitch following TOF stimulation): 2 mg/kg as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Readministration of rocuronium or vecuronium: Following sugammadex use for routine reversal, waiting times for readministration of rocuronium or vecuronium vary greatly (5 minutes to 24 hours) depending on agent, dose, and renal function (consult product labeling); if immediate neuromuscular blockade is needed, a nonsteroidal neuromuscular-blocking agent (eg, cisatracurium or atracurium) may be required.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd8a1138-f7ea-4f62-be6a-1b17b944fb2b">Immediate reversal of rocuronium-induced blockade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immediate reversal of rocuronium-induced blockade:</b>
<b>IV:</b> 16 mg/kg as a single dose administered soon (~3 minutes) after administration of a single dose of rocuronium 1.2 mg/kg. <b>Note: </b>This dose of sugammadex has not been evaluated following administration of vecuronium.</p>
<p style="text-indent:-2em;margin-left:4em;">Readministration of rocuronium or administration of vecuronium: Following sugammadex use for immediate reversal of rocuronium, wait 24 hours before readministering rocuronium or administering vecuronium. If more immediate neuromuscular blockade is needed, a nonsteroidal neuromuscular-blocking agent (eg, cisatracurium or atracurium) may be required.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990736"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl 30 to 80 mL/minute: No dosage adjustment necessary. After administration of up to 4 mg/kg of sugammadex and at least 24 hours has elapsed, a neuromuscular blocking agent (ie, rocuronium 0.6 mg/kg or vecuronium 0.1 mg/kg) may be readministered if necessary. If sooner readministration of a neuromuscular blocking agent is required, rocuronium 1.2 mg/kg may be administered (no dosing recommended for vecuronium).</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt; 30 mL/minute: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Dialysis: Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F50988103"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution, particularly if accompanied by coagulopathy or severe edema.</p></div>
<div class="block adr drugH1Div" id="F23657868"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (5% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (adults: 26%; children and adolescents: 2% to 6%), vomiting (children, adolescents, and adults: 8% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Pain (children, adolescents, and adults: 48% to 59%; includes procedural pain)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (children, adolescents, and adults: 5% to 10%), ECG abnormality (6%, including prolonged QT interval on ECG), hypertension (9%), tachycardia (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (2%), pruritus (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (4% to 6%), flatulence (3%), xerostomia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased red blood cells (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (7% to 9%; including severe hypersensitivity reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (1% to 3%), chills (7%), depression (≤2%), dizziness (3% to 6%), headache (10%), hypoesthesia (3%), insomnia (5%), restlessness (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (1% to 2%), limb pain (6%), musculoskeletal pain (2%), myalgia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (3% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (5% to 9%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis (Ruetzler 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (Ruetzler 2022)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hematologic &amp; oncologic: Increased INR, prolonged partial thromboplastin time, prolonged prothrombin time</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, atrioventricular block, ST segment changes on ECG, supraventricular extrasystole, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Nonimmune anaphylaxis, type I hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, pulmonary edema, wheezing</p></div>
<div class="block coi drugH1Div" id="F23657780"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to sugammadex or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F46021153"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bradycardia: Marked bradycardia and bradycardia with cardiac arrest have been reported, usually within minutes after administration. Monitor closely for hemodynamic changes during and after reversal of neuromuscular blockade; use appropriate pharmacologic treatment (eg, atropine) if significant bradycardia occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious hypersensitivity reactions (including anaphylaxis and anaphylactic shock) have been reported (uncommonly). May occur in patients without prior exposure to sugammadex.</p>
<p style="text-indent:-2em;margin-left:4em;">• Recurrence of neuromuscular blockade: Recurrence of neuromuscular blockade has occurred in controlled trials, usually associated with suboptimal dosing. After initial reversal with sugammadex, continue respiratory monitoring and ensure adequate ventilator support remains accessible following extubation. Potentiation of neuromuscular blockade by other drugs used in the post-operative period should also be considered for the possibility of recurrence.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use caution in patients with cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use caution in patients with hepatic impairment, particularly if accompanied by coagulopathy or severe edema.</p>
<p style="text-indent:-2em;margin-left:4em;">• Impaired hemostasis: Use caution in patients with or at risk for impaired hemostasis (eg, coagulopathies, severe liver impairment, or concurrent use of anticoagulants at therapeutic doses). Dose-dependent transient increases in activated partial thromboplastin time (aPTT) and normalized prothrombin time (PT [INR]) have been observed. In clinical trials, significant effects on bleeding were not observed with low-dose sugammadex alone or in conjunction with therapeutic anticoagulation; high risk patients and those receiving high-dose sugammadex were not adequately studied. Careful monitoring of hemostatic and coagulation parameters is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use is not recommended in patients with severe renal impairment (CrCl &lt;30 mL/minute) or on dialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elderly patients: Use caution in elderly patients; reversal time may be delayed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use in intensive care (ICU) setting has not been evaluated. Do not use sugammadex for neuromuscular blockade induced by nonsteroidal neuromuscular blocking agents (eg, succinylcholine or benzylisoquinolinium compounds) or steroidal agents other than rocuronium or vecuronium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced personnel: Must be administered under supervision of experienced health care provider familiar with its use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Light anesthesia: Signs of light anesthesia (eg, coughing, grimacing, movement, or suckling of tracheal tube) may become apparent when neuromuscular blockade is reversed intentionally in the middle of anesthesia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory function monitoring: Since other drugs (eg, opioids) used in the peri- and post-operative period may depress respiratory function, ventilatory support is mandatory until adequate spontaneous respiration is restored and ability to maintain a patent airway is assured. In addition, some patients experience a delayed or minimal response to recommended doses of sugammadex.</p></div>
<div class="block foc drugH1Div" id="F46127880"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bridion: 200 mg/2 mL (2 mL); 500 mg/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F46128471"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46251917"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Bridion Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/2 mL (per mL): $77.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/5 mL (per mL): $57.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871640"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bridion: 100 mg/mL (2 mL, 5 mL)</p></div>
<div class="block admp drugH1Div" id="F52614542"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;2 years: In one trial, a dilution was administered over 10 seconds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19194156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19194156'])">Ref</a></span>); based on experience in older patients, some experts suggest administering slow IV push to reduce the incidence of serious adverse events (eg, bradycardia, asystole) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29935599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29935599'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: Administer diluted (10 mg/mL) or undiluted (100 mg/mL) over 10 seconds; however, some experts suggest administering slow IV push to reduce the incidence of serious adverse events (eg, bradycardia, asystole) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29935599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29935599'])">Ref</a></span>). If administered in same IV line as other products, flush with saline before and after administration of sugammadex.</p></div>
<div class="block adm drugH1Div" id="F46021173"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer as rapid IV push over 10 seconds (according to the manufacturer); however, some experts suggest administering slow IV push to reduce incidence of serious adverse events (eg, bradycardia or asystole) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29935599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29935599'])">Ref</a></span>). If administered in same IV line as other products, flush with saline before and after administration of sugammadex.</p></div>
<div class="block sts drugH1Div" id="F46021156"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vial at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. When not protected from light, use intact vial within 5 days. Discard any unused portion of a punctured (in-use) vial immediately after use. Solutions diluted for infusion should be used immediately after preparation (<b>Note:</b> Prior to November 2022, the prescribing information stated the diluted solution could be stored for up to 48 hours refrigerated or at room temperature).</p></div>
<div class="block usep drugH1Div" id="F53571093"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Reversal of neuromuscular blockade induced by rocuronium or vecuronium use during surgery (FDA approved in ages ≥2 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F21989949"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F21989947"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Sugammadex may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May diminish the therapeutic effect of Sugammadex.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: Sugammadex may diminish the therapeutic effect of Hormonal Contraceptives.  Management: Patients receiving any hormonal contraceptive (oral or non-oral) should use an additional, nonhormonal contraceptive method during and for 7 days following sugammadex treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: May diminish the therapeutic effect of Sugammadex.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53623693"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The effects of hormonal contraception may be decreased following sugammadex administration. An additional nonhormonal contraceptive (eg, condom, spermicide) should be used for 7 days after a dose of sugammadex in women using oral or nonoral hormonal contraception.</p></div>
<div class="block pri drugH1Div" id="F46021151"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in some animal reproduction studies. Limited information is available related to the use of sugammadex for the reversal of rocuronium-induced neuromuscular blockade after cesarean section (Pühringer 2010; Stourac 2013).</p></div>
<div class="block mopp drugH1Div" id="F53571091"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Neuromuscular stimulation (eg, post-tetanic counts [PTC] and train-of-four [TOF]); ECG monitoring (for bradycardia) during and after administration (Hunter 2018); monitor for anaphylaxis for at least 5 minutes after administration (Tsur 2014); hemostatic and coagulation parameters in select patients; respiratory function during recovery.</p></div>
<div class="block pha drugH1Div" id="F46021159"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sugammadex is a modified gamma cyclodextrin which is a selective relaxant binding agent. It forms a complex with the neuromuscular-blocking agents rocuronium or vecuronium in plasma, reducing the amount of neuromuscular-blocking agent available to bind to nicotinic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium or vecuronium. </p></div>
<div class="block phk drugH1Div" id="F46021160"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: &lt;3 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 and Adolescents &lt;17 years: 3 to 10 L.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 11 to 14 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Negligible.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not metabolized.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric: ~1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult: Effective: ~2 hours; Prolonged in renal impairment: Mild renal impairment: 4 hours; Moderate renal impairment: 6 hours; Severe renal impairment: 19 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (95% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F56215093"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Clearance and volume of distribution increase with increasing age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45854951"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Sugammadex mylan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bridion | Bryony | Dexperta | Lessav | Rebrive | Reverso | Sugamadex sodic blau</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bridion | Sugammadex anfarm | Sugammadex gebro | Sugammadex onkogen | Sugammadex qilu | Sugammadex reddy | Sugammadex teva</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bresis | Bridion</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Sugammadex bnm</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bridion | Sugammadex pharmazac | Sugammadex sandoz | Sugammadex teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Bridion</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bridion | Brimadeks | Sugaver | Sugrino</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Bridion | Myladion | Sumabid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Bridion.1">
<a name="Bridion.1"></a>Bridion (sugammadex) injection [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bridion.2">
<a name="Bridion.2"></a>Bridion solution for injection (sugammadex sodium) [product monograph]. Hertfordshire, UK; Merck Sharp &amp; Dohme Limited; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bridion.3">
<a name="Bridion.3"></a>Bridion solution for injection (sugammadex sodium) [summary of product characteristics]. Haarlem, Netherlands; Merck Sharp &amp; Dohme B.V.; June 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18473711">
<a name="18473711"></a>Donati F. Sugammadex: a cyclodextrin to reverse neuromuscular blockade in anaesthesia. <i>Expert Opin Pharmacother</i>. 2008;9(8):1375-1386.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/18473711/pubmed" id="18473711" target="_blank">18473711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22698066">
<a name="22698066"></a>Geldner G, Niskanen M, Laurila P, et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. <i>Anaesthesia</i>. 2012;67(9):991-998. doi:10.1111/j.1365-2044.2012.07197.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/22698066/pubmed" id="22698066" target="_blank">22698066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27062217">
<a name="27062217"></a>Hotta E, Tamagawa-Mineoka R, Masuda K, et al. Anaphylaxis caused by γ-cyclodextrin in sugammadex. <i>Allergol Int.</i> 2016;65(3):356-358. doi:10.1016/j.alit.2016.02.013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/27062217/pubmed" id="27062217" target="_blank">27062217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29935599">
<a name="29935599"></a>Hunter JM, Naguib M. Sugammadex-induced bradycardia and asystole: how great is the risk? <i>Br J Anaesth.</i> 2018;121(1):8-12. doi:10.1016/j.bja.2018.03.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/29935599/pubmed" id="29935599" target="_blank">29935599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31406051">
<a name="31406051"></a>Matsui M, Konishi J, Suzuki T, Sekijima C, Miyazawa N, Yamamoto S. Reversibility of rocuronium-induced deep neuromuscular block with sugammadex in infants and children-a randomized study. <i>Biol Pharm Bull</i>. 2019;42(10):1637-1640. doi:10.1248/bpb.b19-00044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/31406051/pubmed" id="31406051" target="_blank">31406051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26398716">
<a name="26398716"></a>Monk TG, Rietbergen H, Woo T, Fennema H. Use of sugammadex in patients with obesity: a pooled analysis. <i>Am J Ther.</i> 2017;24(5):e507-e516. doi:10.1097/MJT.0000000000000305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/26398716/pubmed" id="26398716" target="_blank">26398716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26673602">
<a name="26673602"></a>Nakanishi T, Ishida K, Utada K, et al. Anaphylaxis to sugammadex diagnosed by skin prick testing using both sugammadex and a sugammadex-rocuronium mixture.<i> Anaesth Intensive Care.</i> 2016;44(1):122-124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/26673602/pubmed" id="26673602" target="_blank">26673602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19194156">
<a name="19194156"></a>Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. <i>Anesthesiology.</i> 2009;110:284-294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/19194156 /pubmed" id="19194156 " target="_blank">19194156 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20736231">
<a name="20736231"></a>Pühringer FK, Kristen P, Rex C. Sugammadex reversal of rocuronium-induced neuromuscular block in Caesarean section patients: a series of seven cases. <i>Br J Anaesth</i>. 2010;105(5):657-660.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/20736231/pubmed" id="20736231" target="_blank">20736231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25208233">
<a name="25208233"></a>Rahe-Meyer N, Fennema H, Schulman S, et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. <i>Anesthesiology</i>. 2014;121(5):969-977. doi:10.1097/ALN.0000000000000424<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/25208233/pubmed" id="25208233" target="_blank">25208233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35020636">
<a name="35020636"></a>Ruetzler K, Li K, Chhabada S, et al. Sugammadex versus neostigmine for reversal of residual neuromuscular blocks after surgery: a retrospective cohort analysis of postoperative side effects. <i>Anesth Analg</i>. 2022;134(5):1043-1053. doi:10.1213/ANE.0000000000005842<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/35020636/pubmed" id="35020636" target="_blank">35020636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23508494">
<a name="23508494"></a>Stourac P, Krikava I, Seidlova J, et al. Sugammadex in a parturient with myotonic dystrophy. <i>Br J Anaesth</i>. 2013;110(4):657-658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/23508494/pubmed" id="23508494" target="_blank">23508494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24848211">
<a name="24848211"></a>Tsur A, Kalansky A. Hypersensitivity associated with sugammadex administration: a systematic review. <i>Anaesthesia.</i> 2014;69(11):1251-1257. doi:10.1111/anae.12736.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/24848211/pubmed" id="24848211" target="_blank">24848211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27789121">
<a name="27789121"></a>Ue KL, Kasternow B, Wagner A, et al. Sugammadex: An emerging trigger of intraoperative anaphylaxis. <i>Ann Allergy Asthma Immunol.</i> 2016;117(6):714-716. doi:10.1016/j.anai.2016.09.428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sugammadex-pediatric-drug-information/abstract-text/27789121/pubmed" id="27789121" target="_blank">27789121</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 107775 Version 89.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
